×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
DMAC – diamedica therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
DMAC
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/16
05:00 pm
dmac
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/5
09:10 am
dmac
DiaMedica Therapeutics (NASDAQ:DMAC) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
Medium
Report
DiaMedica Therapeutics (NASDAQ:DMAC) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
12/18
09:20 am
dmac
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA [Yahoo! Finance]
Low
Report
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA [Yahoo! Finance]
12/18
08:45 am
dmac
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
Low
Report
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
11/14
09:14 am
dmac
DiaMedica Therapeutics (NASDAQ:DMAC) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Medium
Report
DiaMedica Therapeutics (NASDAQ:DMAC) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
11/13
10:07 am
dmac
DiaMedica signals revised ReMEDy2 trial timeline and expansion cohort completion for DM199 amid cash runway into 2027 [Seeking Alpha]
Medium
Report
DiaMedica signals revised ReMEDy2 trial timeline and expansion cohort completion for DM199 amid cash runway into 2027 [Seeking Alpha]
11/13
10:07 am
dmac
DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
05:11 pm
dmac
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights [Yahoo! Finance]
High
Report
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2025
04:30 pm
DMAC
diamedica therapeutics inc.
MISS
Report
-14.1%
diamedica therapeutics inc.
8/12/2025
04:15 pm
DMAC
diamedica therapeutics inc.
IN-LINE
Report
14.9%
diamedica therapeutics inc.
5/13/2025
04:30 pm
DMAC
diamedica therapeutics inc.
IN-LINE
Report
0.5%
diamedica therapeutics inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/6
05:24 pm
dmac
Form 4 DiaMedica Therapeutics For: Jan 02 Filed by: Parsons James T.
Low
Report
Form 4 DiaMedica Therapeutics For: Jan 02 Filed by: Parsons James T.
1/6
05:24 pm
dmac
Form 4 DiaMedica Therapeutics For: Jan 02 Filed by: Giuffre Randall Michael
Low
Report
Form 4 DiaMedica Therapeutics For: Jan 02 Filed by: Giuffre Randall Michael
1/6
05:22 pm
dmac
Form 4 DiaMedica Therapeutics For: Jan 02 Filed by: Semba Charles Pauling
Low
Report
Form 4 DiaMedica Therapeutics For: Jan 02 Filed by: Semba Charles Pauling
1/5
09:15 am
dmac
Form 8-K DiaMedica Therapeutics For: Jan 05
Medium
Report
Form 8-K DiaMedica Therapeutics For: Jan 05
12/18
08:45 am
dmac
Form 8-K DiaMedica Therapeutics For: Dec 18
Low
Report
Form 8-K DiaMedica Therapeutics For: Dec 18
12/8
05:15 pm
dmac
Form 4 DiaMedica Therapeutics For: Nov 17 Filed by: TRILL AB
Low
Report
Form 4 DiaMedica Therapeutics For: Nov 17 Filed by: TRILL AB
11/25
04:31 pm
dmac
Form 4 DiaMedica Therapeutics For: Nov 21 Filed by: Parsons James T.
Low
Report
Form 4 DiaMedica Therapeutics For: Nov 21 Filed by: Parsons James T.
11/12
04:33 pm
dmac
Form 10-Q DiaMedica Therapeutics For: Sep 30
High
Report
Form 10-Q DiaMedica Therapeutics For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/19
DiaMedica Therapeutics Announces Interim Results from Phase 1b Trial of DM199 in Chronic Kidney Disease Participants
26.7%
10/14 DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease 17.9%
12/17 DiaMedica Therapeutics Announces First Patient Dosed in REDUX Phase II Clinical Trial of DM199 for the Treatment of Chronic Kidney Disease 16.5%
1/3 Form 8-K DiaMedica Therapeutics For: Dec 27 11.8%
1/15 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.6%
8/19 Form 4 DiaMedica Therapeutics For: Aug 19 Filed by: Kellen Scott 8.6%
12/24 Hedge Funds Have Never Been More Bullish On DiaMedica Therapeutics Inc. (DMAC) [Yahoo! Finance News] 8.2%
11/14 DiaMedica Therapeutics Inc. 2019 Q3 - Results - Earnings Call Presentation [Seeking Alpha] 7.6%
3/26 DiaMedica Therapeutics to Present Research at National Kidney Foundation 2020 Spring Clinical Meetings Live Virtual Conference 7.2%
5/14 DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.8%
10/14 DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease 17.9%
12/17 DiaMedica Therapeutics Announces First Patient Dosed in REDUX Phase II Clinical Trial of DM199 for the Treatment of Chronic Kidney Disease 16.5%
1/3 Form 8-K DiaMedica Therapeutics For: Dec 27 11.8%
1/15 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.6%
8/19 Form 4 DiaMedica Therapeutics For: Aug 19 Filed by: Kellen Scott 8.6%
12/24 Hedge Funds Have Never Been More Bullish On DiaMedica Therapeutics Inc. (DMAC) [Yahoo! Finance News] 8.2%
11/14 DiaMedica Therapeutics Inc. 2019 Q3 - Results - Earnings Call Presentation [Seeking Alpha] 7.6%
3/26 DiaMedica Therapeutics to Present Research at National Kidney Foundation 2020 Spring Clinical Meetings Live Virtual Conference 7.2%
5/14 DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.8%
TOP News Decliners
8/13
DiaMedica Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update
-34.7%
11/28 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -13.7%
3/24 DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -12.7%
12/13 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -11.8%
11/13 DiaMedica Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update -8.6%
9/3 DiaMedica Therapeutics to Present at the 2019 Dougherty & Co. Institutional Investor Conference -7.4%
1/3 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.2%
7/16 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.0%
9/6 DiaMedica Therapeutics to Present at Lake Street’s 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019 -6.6%
2/11 Form 424B5 DiaMedica Therapeutics -5.8%
11/28 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -13.7%
3/24 DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -12.7%
12/13 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -11.8%
11/13 DiaMedica Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update -8.6%
9/3 DiaMedica Therapeutics to Present at the 2019 Dougherty & Co. Institutional Investor Conference -7.4%
1/3 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.2%
7/16 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.0%
9/6 DiaMedica Therapeutics to Present at Lake Street’s 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019 -6.6%
2/11 Form 424B5 DiaMedica Therapeutics -5.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: